A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
IMPORTANCE: Semaglutide and tirzepatide, the new generation of glucagon-like peptide-1 receptor agonist used to treat type 2 diabetes and obesity, were recently reported to be associated with increased risk of nonarteritic anterior ischemic optic neu…
Amylin is a peptide hormone co-released with insulin from pancreatic β-cells during a meal and primarily serves to promote satiation. While the caudal hindbrain was originally implicated as a major site of action in this regard, it is becoming increa…
BACKGROUND: -MODY constitutes 5%-10% of MODY cases; however, treatment options remain unclearly recommended, and long-term follow-up of patients with-MODY is lacking due to limited research. Here, we report a case carrying a newvariant of. The patien…
BACKGROUND: As the prevalence of obesity rises among patients with inflammatory bowel disease (IBD), concerns have emerged regarding the gastrointestinal safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are increasingly used for…
INTRODUCTION: Oral semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1 RA) approved for the treatment of type 2 diabetes mellitus (T2DM). Findings from randomized controlled trials (RCTs) and real-world studies indicate that oral semaglu…
GIM/FP/GP: [Formula: see text].
Pasireotide (PAS), a multireceptor somatostatin analog, has been demonstrated to effectively control hormone levels, including those of growth hormone (GH) and insulin-like growth factor 1 (IGF-1), in patients with acromegaly. However, it induces hyp…
BACKGROUND: Gestational diabetes mellitus (GDM) is a widespread pregnancy complication, affecting approximately 7% to 10% of pregnancies worldwide and presenting risks for both maternal and fetal health. Traditional treatments, including lifestyle ch…
INTRODUCTION: IcoSema is under development as a once-weekly injectable combination therapy of icodec (basal insulin) and semaglutide (glucagon-like peptide 1 receptor agonist). This study assessed the pharmacokinetic characteristics of icodec and sem…
Activated protein C (APC) exerts anticoagulant and cytoprotective cell signaling activities. APC's cell signaling requires protease-activated receptor (PAR) PAR1 and PAR3, and APC's PAR cleavages generate peptides capable of agonizing biased G-protei…
BACKGROUND: Whether patients with chronic ankle instability (CAI) can benefit from weight loss yielded by using glucagon-like peptide-1 receptor agonists (GLP1-RAs) has remained unclear. METHODS: In this observational study, we recruited more than 20…
BACKGROUND AND OBJECTIVE: To review pregnancy outcomes in women exposed to semaglutide during early pregnancy. METHODS: A retrospective review of an obstetric database at a tertiary obstetric hospital in Brisbane, Australia. RESULTS: Thirteen women w…
PURPOSE: With the increasing popularity of glucagon-like peptide 1 receptor agonists (GLP1-RAs), numerous safety concerns arose pertaining to suicide, hair loss, and aspiration risks. We attempted to validate these concerns. METHODS: We queried four…
BACKGROUND: Type 2 diabetes (T2D), affecting approximately 12% of the global population and over 30% of older adults, is among the most prevalent and fast-growing risk factors for neurodegenerative disorders. Evidence is lacking on whether specific g…
BACKGROUND: Glucagon-like peptide-1 (GLP-1) therapies are highly effective for weight loss and metabolic improvement in obesity and type 2 diabetes management. However, their use poses clinical challenges, including loss of lean muscle mass and gastr…
Medications like liraglutide 3.0 mg daily (Saxenda®; Novo Nordisk) and semaglutide 2.4 mg weekly (Wegovy®; Novo Nordisk), which are glucagon-like peptide-1 receptor agonists (GLP-1Ra), have been sanctioned for prolonged weight management in people li…